What is a cure and how do we get there?

Area of Science:

• Biotechnology
• Medical Genetics
• Public Health

Background:

• Haemophilia affects 400,000 individuals globally, with limited treatment options, necessitating a cure.
• Advances in molecular science have made gene therapy a feasible approach to curing haemophilia.
• Current therapeutic strategies for haemophilia are complex and face significant hurdles.

Purpose of the Study:

• To explore the feasibility and complexities of developing a gene therapy cure for haemophilia.
• To address the ethical considerations and practical challenges in global clinical trials for haemophilia gene therapy.
• To emphasize the importance of international collaboration and standardized protocols in achieving a cure.

Main Methods:

• Review of recent advances in molecular science relevant to gene therapy.
• Analysis of ethical issues in patient recruitment, informed consent, and geographical variables in global trials.
• Examination of healthcare inequalities and their impact on international medical research.

Main Results:

• Gene therapy presents a viable pathway to curing haemophilia.
• Global clinical trials for haemophilia gene therapy are complex, involving ethical considerations like informed consent and therapeutic misconceptions.
• International healthcare disparities complicate research involving developing countries.

Conclusions:

• Global clinical gene therapy trials are essential for curing haemophilia.
• Ethical conduct, including comprehensive informed consent and clear researcher roles, is paramount.
• Successful global trials require adherence to international standards while considering country-specific cultural and economic factors.